MORC3 and cancer: The distribution of other MSA types in malignancy cases included anti-Mi-2α (n = 3, 60.0%), anti-Mi-2β (n = 2, 28.6%), anti-HMGCR (n = 1, 16.7%), anti-NXP2 (n = 1, 12.5%), and anti-SRP (n = 1, 3.8%) (Figure 2B).